Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3B Multicenter, Randomized, Double-Blind, Double-Dummy Comparative Trial To Evaluate The Efficacy and Safety Of Azithromycin SR (Microspheres Formulation) Versus Moxifloxacin For The Treatment Of Acute Exacerbation Of Chronic Bronchitis (AECB).

NCT00254566 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT00254566
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00254566 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3B Multicenter, Randomized, Double-Blind, Double-Dummy Comparative Trial To Evaluate The Efficacy and Safety Of Azithromycin SR (Microspheres Formulation) Versus Moxifloxacin For The Treatment Of Acute Exacerbation Of Chronic Bronchitis (AECB).
Lead sponsor
Pfizer
Phase
Phase 3
Overall status
Completed
Start date
February 28, 2006
Completion date
August 31, 2008
Enrollment
398 (actual)
Sites
34

Conditions

As the registry lists them; a condition with its own page is linked.

chronic bronchitis